Pioglitazone prevents tau oligomerization

Tadanori Hamano, Norimichi Shirafuji, Chiemi Makino, Shu Hui Yen, Nicholas M. Kanaan, Asako Ueno, Jinya Suzuki, Masamichi Ikawa, Akiko Matsunaga, Osamu Yamamura, Masaru Kuriyama, Yasunari Nakamoto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Tau aggregation and amyloid β protein (Aβ) deposition are the main causes of Alzheimer's disease (AD). Peroxisome proliferator-activated receptor γ (PPARγ) activation modulates Aβ production. To test whether the PPARγ agonist pioglitazone (PIO) is also effective in preventing tau aggregation in AD, we used a cellular model in which wild-type tau protein (4R0N) is overexpressed (M1C cells) (Hamano et al., 2012) as well as primary neuronal cultures. PIO reduced both phosphorylated and total tau levels, and inactivated glycogen synthase kinase 3β, a major tau kinase, associated with activation of Akt. In addition, PIO decreased cleaved caspase3 and C-terminal truncated tau species by caspase, which is expected to decrease tau aggregation. A fractionation study showed that PIO reduced high molecular-weight (120 kDa), oligomeric tau species in Tris Insoluble, sarkosyl-soluble fractions. Tau decrease was reversed by adding GW9662, a PPARγ antagonist. Together, our current results support the idea that PPARγ agonists may be useful therapeutic agents for AD.

Original languageEnglish (US)
Pages (from-to)1035-1042
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume478
Issue number3
DOIs
StatePublished - 2016

Fingerprint

pioglitazone
Oligomerization
Peroxisome Proliferator-Activated Receptors
tau Proteins
Alzheimer Disease
Agglomeration
Chemical activation
Glycogen Synthase Kinase 3
Amyloidogenic Proteins
Serum Amyloid A Protein
Staphylococcal Protein A
Fractionation
Caspases
Phosphotransferases
Molecular Weight
Molecular weight

Keywords

  • Caspase
  • GSK3β
  • Phosphorylation
  • Pioglitazone
  • PPARγ
  • Tau
  • Tau oligomer

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Hamano, T., Shirafuji, N., Makino, C., Yen, S. H., Kanaan, N. M., Ueno, A., ... Nakamoto, Y. (2016). Pioglitazone prevents tau oligomerization. Biochemical and Biophysical Research Communications, 478(3), 1035-1042. https://doi.org/10.1016/j.bbrc.2016.08.016

Pioglitazone prevents tau oligomerization. / Hamano, Tadanori; Shirafuji, Norimichi; Makino, Chiemi; Yen, Shu Hui; Kanaan, Nicholas M.; Ueno, Asako; Suzuki, Jinya; Ikawa, Masamichi; Matsunaga, Akiko; Yamamura, Osamu; Kuriyama, Masaru; Nakamoto, Yasunari.

In: Biochemical and Biophysical Research Communications, Vol. 478, No. 3, 2016, p. 1035-1042.

Research output: Contribution to journalArticle

Hamano, T, Shirafuji, N, Makino, C, Yen, SH, Kanaan, NM, Ueno, A, Suzuki, J, Ikawa, M, Matsunaga, A, Yamamura, O, Kuriyama, M & Nakamoto, Y 2016, 'Pioglitazone prevents tau oligomerization', Biochemical and Biophysical Research Communications, vol. 478, no. 3, pp. 1035-1042. https://doi.org/10.1016/j.bbrc.2016.08.016
Hamano T, Shirafuji N, Makino C, Yen SH, Kanaan NM, Ueno A et al. Pioglitazone prevents tau oligomerization. Biochemical and Biophysical Research Communications. 2016;478(3):1035-1042. https://doi.org/10.1016/j.bbrc.2016.08.016
Hamano, Tadanori ; Shirafuji, Norimichi ; Makino, Chiemi ; Yen, Shu Hui ; Kanaan, Nicholas M. ; Ueno, Asako ; Suzuki, Jinya ; Ikawa, Masamichi ; Matsunaga, Akiko ; Yamamura, Osamu ; Kuriyama, Masaru ; Nakamoto, Yasunari. / Pioglitazone prevents tau oligomerization. In: Biochemical and Biophysical Research Communications. 2016 ; Vol. 478, No. 3. pp. 1035-1042.
@article{788b5923773a432ea3fc561b9dc74db4,
title = "Pioglitazone prevents tau oligomerization",
abstract = "Tau aggregation and amyloid β protein (Aβ) deposition are the main causes of Alzheimer's disease (AD). Peroxisome proliferator-activated receptor γ (PPARγ) activation modulates Aβ production. To test whether the PPARγ agonist pioglitazone (PIO) is also effective in preventing tau aggregation in AD, we used a cellular model in which wild-type tau protein (4R0N) is overexpressed (M1C cells) (Hamano et al., 2012) as well as primary neuronal cultures. PIO reduced both phosphorylated and total tau levels, and inactivated glycogen synthase kinase 3β, a major tau kinase, associated with activation of Akt. In addition, PIO decreased cleaved caspase3 and C-terminal truncated tau species by caspase, which is expected to decrease tau aggregation. A fractionation study showed that PIO reduced high molecular-weight (120 kDa), oligomeric tau species in Tris Insoluble, sarkosyl-soluble fractions. Tau decrease was reversed by adding GW9662, a PPARγ antagonist. Together, our current results support the idea that PPARγ agonists may be useful therapeutic agents for AD.",
keywords = "Caspase, GSK3β, Phosphorylation, Pioglitazone, PPARγ, Tau, Tau oligomer",
author = "Tadanori Hamano and Norimichi Shirafuji and Chiemi Makino and Yen, {Shu Hui} and Kanaan, {Nicholas M.} and Asako Ueno and Jinya Suzuki and Masamichi Ikawa and Akiko Matsunaga and Osamu Yamamura and Masaru Kuriyama and Yasunari Nakamoto",
year = "2016",
doi = "10.1016/j.bbrc.2016.08.016",
language = "English (US)",
volume = "478",
pages = "1035--1042",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Pioglitazone prevents tau oligomerization

AU - Hamano, Tadanori

AU - Shirafuji, Norimichi

AU - Makino, Chiemi

AU - Yen, Shu Hui

AU - Kanaan, Nicholas M.

AU - Ueno, Asako

AU - Suzuki, Jinya

AU - Ikawa, Masamichi

AU - Matsunaga, Akiko

AU - Yamamura, Osamu

AU - Kuriyama, Masaru

AU - Nakamoto, Yasunari

PY - 2016

Y1 - 2016

N2 - Tau aggregation and amyloid β protein (Aβ) deposition are the main causes of Alzheimer's disease (AD). Peroxisome proliferator-activated receptor γ (PPARγ) activation modulates Aβ production. To test whether the PPARγ agonist pioglitazone (PIO) is also effective in preventing tau aggregation in AD, we used a cellular model in which wild-type tau protein (4R0N) is overexpressed (M1C cells) (Hamano et al., 2012) as well as primary neuronal cultures. PIO reduced both phosphorylated and total tau levels, and inactivated glycogen synthase kinase 3β, a major tau kinase, associated with activation of Akt. In addition, PIO decreased cleaved caspase3 and C-terminal truncated tau species by caspase, which is expected to decrease tau aggregation. A fractionation study showed that PIO reduced high molecular-weight (120 kDa), oligomeric tau species in Tris Insoluble, sarkosyl-soluble fractions. Tau decrease was reversed by adding GW9662, a PPARγ antagonist. Together, our current results support the idea that PPARγ agonists may be useful therapeutic agents for AD.

AB - Tau aggregation and amyloid β protein (Aβ) deposition are the main causes of Alzheimer's disease (AD). Peroxisome proliferator-activated receptor γ (PPARγ) activation modulates Aβ production. To test whether the PPARγ agonist pioglitazone (PIO) is also effective in preventing tau aggregation in AD, we used a cellular model in which wild-type tau protein (4R0N) is overexpressed (M1C cells) (Hamano et al., 2012) as well as primary neuronal cultures. PIO reduced both phosphorylated and total tau levels, and inactivated glycogen synthase kinase 3β, a major tau kinase, associated with activation of Akt. In addition, PIO decreased cleaved caspase3 and C-terminal truncated tau species by caspase, which is expected to decrease tau aggregation. A fractionation study showed that PIO reduced high molecular-weight (120 kDa), oligomeric tau species in Tris Insoluble, sarkosyl-soluble fractions. Tau decrease was reversed by adding GW9662, a PPARγ antagonist. Together, our current results support the idea that PPARγ agonists may be useful therapeutic agents for AD.

KW - Caspase

KW - GSK3β

KW - Phosphorylation

KW - Pioglitazone

KW - PPARγ

KW - Tau

KW - Tau oligomer

UR - http://www.scopus.com/inward/record.url?scp=84994017796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994017796&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.08.016

DO - 10.1016/j.bbrc.2016.08.016

M3 - Article

C2 - 27543203

AN - SCOPUS:84994017796

VL - 478

SP - 1035

EP - 1042

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -